The non-binding agreement combines AstraZeneca’s therapeutic knowledge with Oracle’s infrastructure to streamline the journey from drug discovery to patient treatment. Initial efforts will focus on oncology, rare diseases, and cardiovascular, renal, and metabolic conditions. By automating the identification of candidates, the firms hope to reduce the time patients spend waiting for access to experimental therapies.
Oracle and AstraZeneca Forge AI Partnership for Clinical Trials
Recruiting patients for clinical trials remains a primary hurdle in medical research, but a new partnership between AstraZeneca and Oracle aims to bridge that gap. The companies plan to deploy cloud-based AI and real-world data analytics to help clinicians identify eligible patients and integrate research findings directly into daily care.
Executives from both organizations, including AstraZeneca CEO Pascal Soriot and Oracle Health’s Seema Verma, emphasized that the initiative seeks to create a continuous learning model. This framework would allow insights generated during routine clinical care to inform future study designs and safety monitoring. By establishing shared governance and reusable technical components, the partners intend to test whether these digital workflows can be scaled across various geographies and complex disease landscapes.
Comments (0)
No comments yet. Be the first!